Unbearable Lightness? China Levies Record $1.3bn Fine Amid Vaccine Scandal
Executive Summary
Record-breaking fine slapped on scandal-hit domestic vaccine maker in China has some wondering if the tide of opinion may be turning against private companies.
You may also be interested in...
Vaccine Maker Bankruptcy Shows Regulatory Perils Of Business In China
China's Changchun Changsheng Biotech has been officially declared bankrupt, ending long-running speculation. The major vaccine maker’s dramatic fall has several take-away lessons for health companies operating in China, where several new regulations are taking effect.
Oncology Dominates As China Approves Record 48 New Drugs In 2018
Despite multiple adverse factors including a leadership shakeup and the departure of its top regulator, the China FDA seemed determined to refresh itself after a name change and to speed up new drugs to market.
A Shocking Shot: China's Latest Vaccine Forgery More Problematic Than Ever
Just when a fragile sector has barely regained its footing, a new vaccine scandal in China has and come into the national spotlight, and some underlying issues this time could go beyond distribution negligence and regulatory non-compliance.